These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36478438)

  • 1. Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate.
    Lee L; Murase K; Ma J; Thoolen M
    Clin Pharmacol Drug Dev; 2023 Mar; 12(3):279-286. PubMed ID: 36478438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers.
    Gao L; Kaushik D; Ingalls K; Milner S; Smith N; Kong R
    Drugs R D; 2024 Sep; 24(3):477-487. PubMed ID: 39316278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
    Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
    Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
    Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
    J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
    Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
    Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
    Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
    Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
    Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
    Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
    Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.
    Hu M; Lee HK; To KK; Fok BS; Wo SK; Ho CS; Wong CK; Zuo Z; Chan TY; Chan JC; Tomlinson B
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1471-1478. PubMed ID: 27651239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
    Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.
    Murase K; Lee L; Ma J; Barrett R; Thoolen M
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1823-1831. PubMed ID: 36166059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
    Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
    Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
    Gidal BE; Mintzer S; Schwab M; Schutz R; Kharidia J; Blum D; Grinnell T; Sunkaraneni S
    Epilepsy Res; 2017 Sep; 135():64-70. PubMed ID: 28624574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.